JP5784626B2 - 免疫療法および抗腫瘍治療のための新規な結合体および組成物 - Google Patents
免疫療法および抗腫瘍治療のための新規な結合体および組成物 Download PDFInfo
- Publication number
- JP5784626B2 JP5784626B2 JP2012542587A JP2012542587A JP5784626B2 JP 5784626 B2 JP5784626 B2 JP 5784626B2 JP 2012542587 A JP2012542587 A JP 2012542587A JP 2012542587 A JP2012542587 A JP 2012542587A JP 5784626 B2 JP5784626 B2 JP 5784626B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- cells
- fusion protein
- hil15
- apoa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200931158A ES2362062B1 (es) | 2009-12-11 | 2009-12-11 | Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral. |
ESP200931158 | 2009-12-11 | ||
ESP201030813 | 2010-05-27 | ||
ES201030813 | 2010-05-27 | ||
PCT/ES2010/070818 WO2011070214A2 (es) | 2009-12-11 | 2010-12-10 | Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013513377A JP2013513377A (ja) | 2013-04-22 |
JP2013513377A5 JP2013513377A5 (es) | 2014-01-30 |
JP5784626B2 true JP5784626B2 (ja) | 2015-09-24 |
Family
ID=43927978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012542587A Expired - Fee Related JP5784626B2 (ja) | 2009-12-11 | 2010-12-10 | 免疫療法および抗腫瘍治療のための新規な結合体および組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8771664B2 (es) |
EP (1) | EP2511294B1 (es) |
JP (1) | JP5784626B2 (es) |
CN (1) | CN102753574B (es) |
AU (1) | AU2010329805B2 (es) |
BR (1) | BR112012013868A8 (es) |
CA (1) | CA2783876C (es) |
ES (1) | ES2463016T3 (es) |
MX (1) | MX2012006691A (es) |
RU (1) | RU2597989C2 (es) |
WO (1) | WO2011070214A2 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013018046B1 (pt) | 2011-01-18 | 2023-01-31 | Bioniz, Llc | Conjugado peptídico, composição farmacêutica, métodos in vitro para bloquear sinalização por um ou mais membros de família citocina-yc e para inibir ligação de citocina-yc a subunidade-yc e uso de conjugado peptídico ou de composição farmacêutica |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
US11401312B2 (en) * | 2013-04-19 | 2022-08-02 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
CA2954741C (en) | 2013-10-13 | 2023-10-03 | Nova Southeastern University | Identification of a natural killer cell population as potential therapeutic targets for gulf war illness and myalgic encephalomyelitis/chronic fatigue syndrome |
US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
PL3094351T3 (pl) * | 2014-01-15 | 2022-06-27 | Kadmon Corporation, Llc | Środki immunomodulujące |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
WO2015164107A1 (en) | 2014-04-23 | 2015-10-29 | Emory University | Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto |
WO2016200881A1 (en) | 2015-06-10 | 2016-12-15 | Emory University | Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta |
CN106317225A (zh) * | 2015-06-28 | 2017-01-11 | 复旦大学 | 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途 |
HUE056544T2 (hu) | 2015-10-09 | 2022-02-28 | Bioniz Llc | Gamma-C-citokin aktivitás modulálása |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
AU2017283480A1 (en) | 2016-06-13 | 2019-01-24 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
US11524033B2 (en) | 2017-09-05 | 2022-12-13 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
CA3086040A1 (en) * | 2017-12-19 | 2019-06-27 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
WO2023064469A1 (en) * | 2021-10-13 | 2023-04-20 | Modernatx, Inc. | Compositions of mrna-encoded il15 fusion proteins and methods of use thereof |
WO2024036145A1 (en) * | 2022-08-07 | 2024-02-15 | Protean Bio, Inc. | Peptides for beta-cell survival and insulin production |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0238645A1 (en) * | 1985-10-03 | 1987-09-30 | Biotechnology Research Partners, Ltd. | Novel lipoprotein-based drug-delivery systems |
US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
US5747024A (en) | 1993-03-08 | 1998-05-05 | Immunex Corporation | Vaccine adjuvant comprising interleukin-15 |
DE69628154T2 (de) | 1995-03-08 | 2004-03-18 | The Scripps Research Institute, La Jolla | Antigen präsentierendes system und aktivierung von t-zellen |
US6787154B2 (en) | 1998-10-20 | 2004-09-07 | Salvatore Albani | Artificial antigen presenting cells |
AU2008201887B2 (en) * | 2000-11-10 | 2011-06-30 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
EP2343317A1 (en) * | 2000-11-10 | 2011-07-13 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
EP1718282A4 (en) | 2004-01-15 | 2010-07-14 | Sinai School Medicine | PROCESS AND COMPOSITIONS FOR IMAGE PRESENTATION |
WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
US20060257361A1 (en) | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
WO2007069090A2 (en) | 2005-12-06 | 2007-06-21 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
AU2007274035A1 (en) | 2006-07-13 | 2008-01-17 | Novozymes Biopharma Dk A/S | Process for preparing particles of proteinaceous material |
KR100817024B1 (ko) | 2006-11-09 | 2008-03-26 | 재단법인 목암생명공학연구소 | 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물 |
JP5685529B2 (ja) | 2008-06-13 | 2015-03-18 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダProyecto De Biomedicina Cima, S.L. | 生物学的活性を有する化合物の投与のための複合体 |
-
2010
- 2010-12-10 WO PCT/ES2010/070818 patent/WO2011070214A2/es active Application Filing
- 2010-12-10 BR BR112012013868A patent/BR112012013868A8/pt not_active Application Discontinuation
- 2010-12-10 CN CN201080061939.9A patent/CN102753574B/zh not_active Expired - Fee Related
- 2010-12-10 ES ES10814739.8T patent/ES2463016T3/es active Active
- 2010-12-10 US US13/514,855 patent/US8771664B2/en not_active Expired - Fee Related
- 2010-12-10 JP JP2012542587A patent/JP5784626B2/ja not_active Expired - Fee Related
- 2010-12-10 RU RU2012129208/10A patent/RU2597989C2/ru not_active IP Right Cessation
- 2010-12-10 CA CA2783876A patent/CA2783876C/en not_active Expired - Fee Related
- 2010-12-10 EP EP10814739.8A patent/EP2511294B1/en active Active
- 2010-12-10 AU AU2010329805A patent/AU2010329805B2/en not_active Ceased
- 2010-12-10 MX MX2012006691A patent/MX2012006691A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
RU2012129208A (ru) | 2014-01-20 |
ES2463016T3 (es) | 2014-05-27 |
US20120244118A1 (en) | 2012-09-27 |
AU2010329805B2 (en) | 2016-07-14 |
RU2597989C2 (ru) | 2016-09-20 |
JP2013513377A (ja) | 2013-04-22 |
CA2783876C (en) | 2018-04-03 |
BR112012013868A2 (pt) | 2017-01-10 |
AU2010329805A1 (en) | 2012-07-05 |
CN102753574A (zh) | 2012-10-24 |
WO2011070214A8 (es) | 2011-09-29 |
MX2012006691A (es) | 2013-02-26 |
EP2511294A2 (en) | 2012-10-17 |
BR112012013868A8 (pt) | 2017-12-26 |
EP2511294B1 (en) | 2014-02-26 |
CN102753574B (zh) | 2015-05-20 |
WO2011070214A2 (es) | 2011-06-16 |
US8771664B2 (en) | 2014-07-08 |
CA2783876A1 (en) | 2011-06-16 |
WO2011070214A3 (es) | 2011-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5784626B2 (ja) | 免疫療法および抗腫瘍治療のための新規な結合体および組成物 | |
EP3307783B1 (en) | Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta | |
Nelms et al. | The IL-4 receptor: signaling mechanisms and biologic functions | |
ES2862139T3 (es) | Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos | |
ES2315008T3 (es) | Composiciones que contienen un agente de union a receptor ox-40 o un acido nucleido que codifica el mismo y procedimientos para potenciar la respuesta inmune especifica de antigeno. | |
ES2268863T3 (es) | Receptores quimericos. | |
KR20180089516A (ko) | 인터류킨-15 조성물 및 이의 용도 | |
AU2007216170A1 (en) | Molecules and methods of using same for treating CCR5/CCR5 ligands associated diseases | |
AU733719B2 (en) | Improved vaccines | |
KR20160016725A (ko) | 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포 | |
MX2010012746A (es) | Molecula adaptadora para la administracion de vectores de adenovirus. | |
WO2018162450A1 (en) | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells | |
JP2021501221A (ja) | 免疫チェックポイント経路阻害剤と併用したインターロイキン−10の組成物および使用方法 | |
EP2374813A1 (en) | Use of phenol-soluble modulins for vaccine development | |
ES2348674T3 (es) | Miembros de la familia del receptor similar a ig leucociteno modificado (lir) con afinidad incrementada para mhc clase i y sus usos en la modulaciã“n de la activaciã“n de cã‰lula t. | |
ES2362062A1 (es) | Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131203 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150605 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150626 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150722 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5784626 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |